Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc V.VIV.H

Alternate Symbol(s):  VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV.H - Post by User

Post by StoneMan45on Oct 18, 2021 8:48am
179 Views
Post# 34017151

6.3 tonne order represents a 43% increase

6.3 tonne order represents a 43% increase
Avivagen Secures Large OxC-betaTM Livestock Order in Asia
 
  • 6.3 tonne order represents a 43% increase over most recent shipment to same customer
  • Growth during pandemic signals strong impact on market share through use of OxC-betaTM
 
Ottawa, ON / Business Wire/ October 18, 2021 // Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it has signed a significant new purchase agreement to supply its largest customer in Asia with a 6.3 tonne order of OxC-betaTM Livestock. The shipment represents a 43% increase in size over the customer’s previous order and continues a trend of increased reorder size among this and other OxC-betaTM customers worldwide.   
 
“We’re extremely pleased to see the continued growth of this important customer in Asia, one of the most important regions worldwide for livestock feed production,” says Kym Anthony, Chief Executive Officer, Aviagen Inc. “We believe that the fact that Avivagen’s customers continue to increase order size for OxC-betaTM amid a global pandemic is a clear sign of the positive impact that integration of our products can have on our customer’s bottom line.  We’re excited by the growth potential ahead of us in both Asia and around the world.”

<< Previous
Bullboard Posts
Next >>